Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caris Life Sciences (CAI) Interest & Investment Income (2024 - 2025)

Caris Life Sciences has reported Interest & Investment Income over the past 2 years, most recently at $7.0 million for Q4 2025.

  • Quarterly results put Interest & Investment Income at $7.0 million for Q4 2025, up 623.2% from a year ago — trailing twelve months through Dec 2025 was $17.0 million (changed N/A YoY), and the annual figure for FY2025 was $16.5 million, up 131.63%.
  • Interest & Investment Income for Q4 2025 was $7.0 million at Caris Life Sciences, down from $7.4 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for CAI hit a ceiling of $7.4 million in Q3 2025 and a floor of $970000.0 in Q4 2024.